Flyer: Introducing Eurofins Beacon Discovery; the GPCR experts
Posted: 17 September 2021 | Eurofins Discovery | No comments yet
Learn how you can partner for success with Eurofins Beacon Discovery’s industry leading GPCR experts to support your program from concept to clinic.
Eurofins Beacon Discovery is an industry leader in GPCR drug discovery offering an integrated approach for challenging GPCR targets. The Beacon Team has identified in excess of 30 pre-clinical candidates of which more than 20 programs have moved successfully into clinical development. Beacon Discovery employs an integrated workflow that will fully support your discovery program. Learn how you can take advantage of Eurofins Beacon Discovery’s capabilities now!
Related content from this organisation
- The future of carcinogenicity risk assessment: AI-powered, ethical alternatives to traditional testing
- Unprecedented fragment-based screening using Spectral Shift for GPCRs
- Rapid functional cell-based activity profiling of multi-receptor targeted anti-obesity therapies
- CRISPR™ MDCKII cell lines development for bioavailability and DDI assessments
- SAFIRE: AI predicted ADME for drug discovery: leveraging BioPrint
Related topics
Assays, Disease Research, GPCRs, High-Throughput Screening (HTS), Hit-to-Lead, Immunology, In Vivo, Informatics, Screening, Targets
Related organisations
Eurofins Discovery
